The case of Abbokinase and the FDA: the events leading to the suspension of Abbokinase supplies in the United States

J Vasc Interv Radiol. 2000 Jul-Aug;11(7):841-7. doi: 10.1016/s1051-0443(07)61798-9.

Authors

G G Hartnell¹, J Gates

Affiliation

¹ Department of Radiology, Johns Hopkins Hospital, Baltimore, Maryland, USA. gandjhartnell@erols.com

PMID: 10928519
DOI: 10.1016/s1051-0443(07)61798-9

No abstract available

MeSH terms

Cells, Cultured
Drug Approval*
Drug Industry / standards
Fibrinolytic Agents / adverse effects
Fibrinolytic Agents / chemical synthesis
Fibrinolytic Agents / supply & distribution
Humans
Kidney
Plasminogen Activators / adverse effects
Plasminogen Activators / chemical synthesis
Plasminogen Activators / supply & distribution*
United States
United States Food and Drug Administration* / standards
Urokinase-Type Plasminogen Activator / adverse effects
Urokinase-Type Plasminogen Activator / chemical synthesis
Urokinase-Type Plasminogen Activator / supply & distribution*

Substances

Fibrinolytic Agents
Plasminogen Activators
Urokinase-Type Plasminogen Activator